Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers.
ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring its combination with other therapies.
This research is crucial for advancing ERNA-101 toward regulatory submission. The company (https://www.eternatx.com/) is focused on developing innovative, safe, off-the-shelf cell therapies for advanced solid tumors.
Listen to our latest podcast for full details: